MedPath

Seprafilm® for Prevention of Adhesions at Repeat Cesarean

Phase 3
Terminated
Conditions
Adhesion Formation After Primary Cesarean Delivery
Interventions
Other: Control
Device: Seprafilm®
Registration Number
NCT00697606
Lead Sponsor
Abington Memorial Hospital
Brief Summary

Adhesion formation is a result of abdominal and pelvic surgery and is a cause of such diseases as chronic pain syndrome, bowel obstruction and infertility. Both patients and surgeons suffer when adhesions are encountered, since the surgery becomes more intense, lengthy, and complicated. Seprafilm® has been shown to limit the formation of adhesions in gynecologic and abdominal surgery. Limited data is available on the effectiveness of Seprafilm® in the prevention of abdominal wall and pelvic adhesions at the time of cesarean section. Adhesions at the time of repeat cesarean make the surgery frustrating and complex, with difficult lysis of adhesions being the cause of morbidities such as bladder damage, increased blood loss, and longer operating times. The objective of this definitive project is to define the extent of reduction of adhesion formation of Seprafilm® when used at the time of primary cesarean section. Women undergoing primary cesarean section will be randomized for Seprafilm® application, and the incidence and grade of adhesions at repeat cesarean will be determined.

Detailed Description

This is a prospective randomized double-blinded study. Patients will be randomized prior to primary cesarean section to either the study arm (Seprafilm® placement) or control arm (nothing placed). Seprafilm® will be placed over the repaired uterine incision and over the anterior aspect of the uterus prior to closure of the fascia (2 to 3 sheets per patient). Randomization will be by opaque envelops containing group assignment.

Participants and surgeons will be blinded to group designation at the time of repeat cesarean. The surgeon will be asked to grade the adhesions at the time of repeat cesarean.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
450
Inclusion Criteria
  1. Pregnant women after 24 weeks' gestation.
  2. First cesarean delivery.
  3. Age > 18 years.
  4. Cesarean to be performed by a participating surgeon.
  5. Non-closure of the visceral or parietal peritoneum.
Read More
Exclusion Criteria
  1. Any prior abdominal surgery including prior cesarean, laparoscopy, appendectomy, cholecystectomy or any uterine adnexal or bowel surgery.
  2. Clinical diagnosis of chorioamnionitis.
  3. Women having tubal ligation at the time of primary cesarean.
  4. Inability to obtain informed consent.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BControlControl
ASeprafilm®Seprafilm®
Primary Outcome Measures
NameTimeMethod
To determine if Seprafilm® decreases the incidence of adhesion formation by 50% after primary cesarean.at repeat cesarean
Secondary Outcome Measures
NameTimeMethod
To evaluate complication rates in those with Seprafilm® versus those without during repeat surgery by examining length of operating times, blood loss, bladder injuries, and Apgar scoresat repeat cesarean
To determine to what extent Seprafilm® decreases the incidence of adhesion formation.at repeat cesarean
To determine the incidence of adhesion formation during repeat cesarean delivery.at repeat cesarean
To determine the incidence of fertility issues in women having Seprafilm® placed during primary cesarean delivery versus those not having Seprafilm® placed. Participating women will be contacted by telephone every 4 months.ongoing during trial

Trial Locations

Locations (1)

Abington Memorial Hospital

🇺🇸

Abington, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath